All In Biotech

Drug Trial Radar · NCT07574385

Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy

A Phase 2, Randomized, Double-blind, Active-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of ALX006 for Postsurgical Pain Management When Administered as a Sciatic (in the Popliteal Fossa) Nerve Block in Subjects Undergoing a Bunionectomy

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Rebel Medicine IncIndustry
Sponsor type
Industry
First posted
May 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, active-controlled, dose-escalation study evaluating the safety, pharmacokinetics, efficacy, and pharmacodynamics of ALX006, an extended-release bupivacaine formulation, administered as a single-dose sciatic nerve block in the popliteal fossa in adult subjects undergoing primary unilateral bunionectomy. Approximately 60 subjects will be enrolled across 3 sequential dose cohorts (100 mg, 150 mg, 200 mg ALX006), with each cohort comparing ALX006 against MARCAINE 0.25% (bupivacaine HCl 50 mg) as the active comparator at a 3:1 randomization ratio. Dose escalation between cohorts is governed by an Independent Data Monitoring Committee.

Conditions

  • Hallux Valgus
  • Bunionectomy

Interventions

  • ALX006 (bupivacaine extended-release injection)Drug

    ALX006 (50 mg/mL bupivacaine free base)

  • Bupivacaine Hcl 0.25% InjDrug

    Bupivacaine HCl 0.25% plain (2.5 mg/mL)

  • Sciatic Nerve BlockProcedure

    Sciatic nerve block in the popliteal fossa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: From start of nerve block procedure through 360 Hour Visit (Day 15)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel Salt Lake City

    Millcreek, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.